New combo therapy aims to stall advanced lung cancer
NCT ID NCT07567313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a targeted chemoembolization procedure to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 participants who have already responded to initial treatment will be randomly assigned to receive either immunotherapy alone or immunotherapy plus the procedure. The goal is to see if the combination improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (immunotherapy) and bronchial artery chemoembolization (BACE, a procedure to deliver chemotherapy directly to lung tumors)
- What this could lead to
- If successful, this could offer a new treatment option that extends progression-free survival for people with advanced lung squamous cell carcinoma.
- What could go wrong
- This is an early-stage trial with only 166 participants, so results may not apply to everyone. The added procedure carries risks like bleeding or infection, and the benefit over standard immunotherapy alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG SQUAMOUS CELL CARCINOMA STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.